{"entity":{"type":"insider","cik":"0001574591","url":"/insider/0001574591","json_url":"/insider/0001574591.json","name":"Dier Mardi","name_source":"as-filed","also_issuer":false,"cross_url":null},"coverage_statement":{"n_transactions":63,"n_filings":29,"first":"2014-03-27","last":"2026-03-06","span_basis":"filed_date"},"name_variants":[{"name":"Dier Mardi","source":"filing","n_filings":29,"first_seen":"2014-03-27","last_seen":"2026-03-06"}],"transactions":[{"id":5863585,"accession":"0001628280-26-015775","txn_seq":13,"anchor":"line-13","filing_url":"/filing/0001628280-26-015775","line_url":"/filing/0001628280-26-015775","is_derivative":false,"issuer_cik":"0001157601","issuer_name":"MADRIGAL PHARMACEUTICALS, INC.","issuer_ticker":"MDGL","issuer_name_source":null,"issuer_url":"/issuer/0001157601","owner_cik":"0001574591","owner_name":"Dier Mardi","owner_display_name":"Dier Mardi","owner_url":"/insider/0001574591","role":"Officer (EVP and CFO)","role_mark":"O","role_mark_label":"Officer (EVP and CFO)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"EVP and CFO","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1982.0,"shares_display":"1,982","price_per_share":430.87412532795156,"price_display":"430.87","price_state":"stated","total_value":853992.5164,"total_display":"853,992.52","total_whole":"853,993","shares_owned_after":13826.0,"shares_owned_after_display":"13,826","ownership_form":"D","is_10b5_1":null,"transaction_date":"2026-03-06","filed_date":"2026-03-06","scope":"insider","n_lines":12},{"id":6218709,"accession":"0001628280-26-013394","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001628280-26-013394","line_url":"/filing/0001628280-26-013394#line-1","is_derivative":false,"issuer_cik":"0001157601","issuer_name":"MADRIGAL PHARMACEUTICALS, INC.","issuer_ticker":"MDGL","issuer_name_source":null,"issuer_url":"/issuer/0001157601","owner_cik":"0001574591","owner_name":"Dier Mardi","owner_display_name":"Dier Mardi","owner_url":"/insider/0001574591","role":"Officer (EVP and CFO)","role_mark":"O","role_mark_label":"Officer (EVP and CFO)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"EVP and CFO","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1183.0,"shares_display":"1,183","price_per_share":427.21,"price_display":"427.21","price_state":"stated","total_value":505389.43,"total_display":"505,389.43","total_whole":"505,389","shares_owned_after":9257.0,"shares_owned_after_display":"9,257","ownership_form":"D","is_10b5_1":null,"transaction_date":"2026-03-02","filed_date":"2026-03-02","scope":"insider"},{"id":4504717,"accession":"0001628280-25-055164","txn_seq":16,"anchor":"line-16","filing_url":"/filing/0001628280-25-055164","line_url":"/filing/0001628280-25-055164","is_derivative":false,"issuer_cik":"0001157601","issuer_name":"MADRIGAL PHARMACEUTICALS, INC.","issuer_ticker":"MDGL","issuer_name_source":null,"issuer_url":"/issuer/0001157601","owner_cik":"0001574591","owner_name":"Dier Mardi","owner_display_name":"Dier Mardi","owner_url":"/insider/0001574591","role":"Officer (EVP and CFO)","role_mark":"O","role_mark_label":"Officer (EVP and CFO)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"EVP and CFO","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":4173.0,"shares_display":"4,173","price_per_share":578.3408607476636,"price_display":"578.34","price_state":"stated","total_value":2413416.4119,"total_display":"2,413,416.41","total_whole":"2,413,416","shares_owned_after":12812.0,"shares_owned_after_display":"12,812","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-12-02","filed_date":"2025-12-03","scope":"insider","n_lines":15},{"id":4959553,"accession":"0001628280-25-012369","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001628280-25-012369","line_url":"/filing/0001628280-25-012369#line-1","is_derivative":false,"issuer_cik":"0001157601","issuer_name":"MADRIGAL PHARMACEUTICALS, INC.","issuer_ticker":"MDGL","issuer_name_source":null,"issuer_url":"/issuer/0001157601","owner_cik":"0001574591","owner_name":"Dier Mardi","owner_display_name":"Dier Mardi","owner_url":"/insider/0001574591","role":"Officer (SVP and CFO)","role_mark":"O","role_mark_label":"Officer (SVP and CFO)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"SVP and CFO","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":258.0,"shares_display":"258","price_per_share":323.04,"price_display":"323.04","price_state":"stated","total_value":83344.32,"total_display":"83,344.32","total_whole":"83,344","shares_owned_after":10440.0,"shares_owned_after_display":"10,440","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-03-10","filed_date":"2025-03-12","scope":"insider"},{"id":4728953,"accession":"0001628280-25-010508","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001628280-25-010508","line_url":"/filing/0001628280-25-010508","is_derivative":false,"issuer_cik":"0001157601","issuer_name":"MADRIGAL PHARMACEUTICALS, INC.","issuer_ticker":"MDGL","issuer_name_source":null,"issuer_url":"/issuer/0001157601","owner_cik":"0001574591","owner_name":"Dier Mardi","owner_display_name":"Dier Mardi","owner_url":"/insider/0001574591","role":"Officer (SVP and CFO)","role_mark":"O","role_mark_label":"Officer (SVP and CFO)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"SVP and CFO","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1961.0,"shares_display":"1,961","price_per_share":324.9607658337583,"price_display":"324.96","price_state":"stated","total_value":637248.0618,"total_display":"637,248.06","total_whole":"637,248","shares_owned_after":7688.0,"shares_owned_after_display":"7,688","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-03-03","filed_date":"2025-03-05","scope":"insider","n_lines":2},{"id":7869727,"accession":"0001209191-23-028864","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001209191-23-028864","line_url":"/filing/0001209191-23-028864","is_derivative":false,"issuer_cik":"0001574591","issuer_name":"ACELYRIN, Inc.","issuer_ticker":"SLRN","issuer_name_source":null,"issuer_url":"/issuer/0001574591","owner_cik":"0001574591","owner_name":"Dier Mardi","owner_display_name":"Dier Mardi","owner_url":"/insider/0001574591","role":"Officer (CFO and CBO)","role_mark":"O","role_mark_label":"Officer (CFO and CBO)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"CFO and CBO","security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":7306.0,"shares_display":"7,306","price_per_share":18.0,"price_display":"18.00","price_state":"stated","total_value":131508.0,"total_display":"131,508.00","total_whole":"131,508","shares_owned_after":5556.0,"shares_owned_after_display":"5,556","ownership_form":"D","is_10b5_1":null,"transaction_date":"2023-05-09","filed_date":"2023-05-11","scope":"insider","n_lines":3},{"id":6613708,"accession":"0001209191-22-053884","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-22-053884","line_url":"/filing/0001209191-22-053884#line-1","is_derivative":false,"issuer_cik":"0001515673","issuer_name":"Ultragenyx Pharmaceutical Inc.","issuer_ticker":"RARE","issuer_name_source":null,"issuer_url":"/issuer/0001515673","owner_cik":"0001574591","owner_name":"Dier Mardi","owner_display_name":"Dier Mardi","owner_url":"/insider/0001574591","role":"Officer (CFO & Executive Vice President)","role_mark":"O","role_mark_label":"Officer (CFO & Executive Vice President)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"CFO & Executive Vice President","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1629.0,"shares_display":"1,629","price_per_share":40.16,"price_display":"40.16","price_state":"stated","total_value":65420.64,"total_display":"65,420.64","total_whole":"65,421","shares_owned_after":66695.0,"shares_owned_after_display":"66,695","ownership_form":"D","is_10b5_1":null,"transaction_date":"2022-10-14","filed_date":"2022-10-17","scope":"insider"},{"id":6212768,"accession":"0001209191-22-053647","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-22-053647","line_url":"/filing/0001209191-22-053647#line-1","is_derivative":false,"issuer_cik":"0001515673","issuer_name":"Ultragenyx Pharmaceutical Inc.","issuer_ticker":"RARE","issuer_name_source":null,"issuer_url":"/issuer/0001515673","owner_cik":"0001574591","owner_name":"Dier Mardi","owner_display_name":"Dier Mardi","owner_url":"/insider/0001574591","role":"Officer (CFO & Executive Vice President)","role_mark":"O","role_mark_label":"Officer (CFO & Executive Vice President)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"CFO & Executive Vice President","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":3484.0,"shares_display":"3,484","price_per_share":38.22,"price_display":"38.22","price_state":"stated","total_value":133158.48,"total_display":"133,158.48","total_whole":"133,158","shares_owned_after":68324.0,"shares_owned_after_display":"68,324","ownership_form":"D","is_10b5_1":null,"transaction_date":"2022-10-12","filed_date":"2022-10-14","scope":"insider"},{"id":6424457,"accession":"0001209191-22-015833","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001209191-22-015833","line_url":"/filing/0001209191-22-015833#line-3","is_derivative":false,"issuer_cik":"0001515673","issuer_name":"Ultragenyx Pharmaceutical Inc.","issuer_ticker":"RARE","issuer_name_source":null,"issuer_url":"/issuer/0001515673","owner_cik":"0001574591","owner_name":"Dier Mardi","owner_display_name":"Dier Mardi","owner_url":"/insider/0001574591","role":"Officer (CFO & Executive Vice President)","role_mark":"O","role_mark_label":"Officer (CFO & Executive Vice President)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"CFO & Executive Vice President","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":420.0,"shares_display":"420","price_per_share":64.55,"price_display":"64.55","price_state":"stated","total_value":27111.0,"total_display":"27,111.00","total_whole":"27,111","shares_owned_after":51808.0,"shares_owned_after_display":"51,808","ownership_form":"D","is_10b5_1":null,"transaction_date":"2022-03-03","filed_date":"2022-03-03","scope":"insider"},{"id":6424453,"accession":"0001209191-22-015833","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-22-015833","line_url":"/filing/0001209191-22-015833#line-2","is_derivative":false,"issuer_cik":"0001515673","issuer_name":"Ultragenyx Pharmaceutical Inc.","issuer_ticker":"RARE","issuer_name_source":null,"issuer_url":"/issuer/0001515673","owner_cik":"0001574591","owner_name":"Dier Mardi","owner_display_name":"Dier Mardi","owner_url":"/insider/0001574591","role":"Officer (CFO & Executive Vice President)","role_mark":"O","role_mark_label":"Officer (CFO & Executive Vice President)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"CFO & Executive Vice President","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":534.0,"shares_display":"534","price_per_share":66.62,"price_display":"66.62","price_state":"stated","total_value":35575.08,"total_display":"35,575.08","total_whole":"35,575","shares_owned_after":38228.0,"shares_owned_after_display":"38,228","ownership_form":"D","is_10b5_1":null,"transaction_date":"2022-03-01","filed_date":"2022-03-03","scope":"insider"},{"id":5406035,"accession":"0001209191-21-060504","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-21-060504","line_url":"/filing/0001209191-21-060504#line-2","is_derivative":false,"issuer_cik":"0001515673","issuer_name":"Ultragenyx Pharmaceutical Inc.","issuer_ticker":"RARE","issuer_name_source":null,"issuer_url":"/issuer/0001515673","owner_cik":"0001574591","owner_name":"Dier Mardi","owner_display_name":"Dier Mardi","owner_url":"/insider/0001574591","role":"Officer (CFO & Executive Vice President)","role_mark":"O","role_mark_label":"Officer (CFO & Executive Vice President)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"CFO & Executive Vice President","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":3261.0,"shares_display":"3,261","price_per_share":81.16,"price_display":"81.16","price_state":"stated","total_value":264662.76,"total_display":"264,662.76","total_whole":"264,663","shares_owned_after":38762.0,"shares_owned_after_display":"38,762","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-10-14","filed_date":"2021-10-14","scope":"insider"},{"id":5406032,"accession":"0001209191-21-060504","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-21-060504","line_url":"/filing/0001209191-21-060504#line-1","is_derivative":false,"issuer_cik":"0001515673","issuer_name":"Ultragenyx Pharmaceutical Inc.","issuer_ticker":"RARE","issuer_name_source":null,"issuer_url":"/issuer/0001515673","owner_cik":"0001574591","owner_name":"Dier Mardi","owner_display_name":"Dier Mardi","owner_url":"/insider/0001574591","role":"Officer (CFO & Executive Vice President)","role_mark":"O","role_mark_label":"Officer (CFO & Executive Vice President)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"CFO & Executive Vice President","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":3477.0,"shares_display":"3,477","price_per_share":82.79,"price_display":"82.79","price_state":"stated","total_value":287860.83,"total_display":"287,860.83","total_whole":"287,861","shares_owned_after":42023.0,"shares_owned_after_display":"42,023","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-10-12","filed_date":"2021-10-14","scope":"insider"},{"id":2112109,"accession":"0001209191-20-052403","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-20-052403","line_url":"/filing/0001209191-20-052403#line-1","is_derivative":false,"issuer_cik":"0001574591","issuer_name":"Prelude Therapeutics Inc","issuer_ticker":"PRLD","issuer_name_source":null,"issuer_url":"/issuer/0001574591","owner_cik":"0001574591","owner_name":"Dier Mardi","owner_display_name":"Dier Mardi","owner_url":"/insider/0001574591","role":"Director","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":10000.0,"shares_display":"10,000","price_per_share":19.0,"price_display":"19.00","price_state":"stated","total_value":190000.0,"total_display":"190,000.00","total_whole":"190,000","shares_owned_after":10000.0,"shares_owned_after_display":"10,000","ownership_form":"D","is_10b5_1":null,"transaction_date":"2020-09-29","filed_date":"2020-09-29","scope":"insider"},{"id":8675375,"accession":"0001209191-19-024043","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-19-024043","line_url":"/filing/0001209191-19-024043#line-1","is_derivative":false,"issuer_cik":"0001269021","issuer_name":"PORTOLA PHARMACEUTICALS INC","issuer_ticker":"PTLA","issuer_name_source":null,"issuer_url":"/issuer/0001269021","owner_cik":"0001574591","owner_name":"Dier Mardi","owner_display_name":"Dier Mardi","owner_url":"/insider/0001574591","role":"Officer (EVP, CFO & CBO)","role_mark":"O","role_mark_label":"Officer (EVP, CFO & CBO)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"EVP, CFO & CBO","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":40486.0,"shares_display":"40,486","price_per_share":37.3913,"price_display":"37.39","price_state":"stated","total_value":1513824.1718,"total_display":"1,513,824.17","total_whole":"1,513,824","shares_owned_after":66733.0,"shares_owned_after_display":"66,733","ownership_form":"D","is_10b5_1":null,"transaction_date":"2019-04-04","filed_date":"2019-04-08","scope":"insider"},{"id":4083867,"accession":"0001209191-17-045083","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-17-045083","line_url":"/filing/0001209191-17-045083#line-2","is_derivative":false,"issuer_cik":"0001269021","issuer_name":"PORTOLA PHARMACEUTICALS INC","issuer_ticker":"PTLA","issuer_name_source":null,"issuer_url":"/issuer/0001269021","owner_cik":"0001574591","owner_name":"Dier Mardi","owner_display_name":"Dier Mardi","owner_url":"/insider/0001574591","role":"Officer (Executive VP and CFO)","role_mark":"O","role_mark_label":"Officer (Executive VP and CFO)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Executive VP and CFO","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":23350.0,"shares_display":"23,350","price_per_share":60.0,"price_display":"60.00","price_state":"stated","total_value":1401000.0,"total_display":"1,401,000.00","total_whole":"1,401,000","shares_owned_after":0.0,"shares_owned_after_display":"0","ownership_form":"D","is_10b5_1":null,"transaction_date":"2017-07-11","filed_date":"2017-07-13","scope":"insider"},{"id":4990186,"accession":"0001209191-17-042169","txn_seq":8,"anchor":"line-8","filing_url":"/filing/0001209191-17-042169","line_url":"/filing/0001209191-17-042169","is_derivative":false,"issuer_cik":"0001269021","issuer_name":"PORTOLA PHARMACEUTICALS INC","issuer_ticker":"PTLA","issuer_name_source":null,"issuer_url":"/issuer/0001269021","owner_cik":"0001574591","owner_name":"Dier Mardi","owner_display_name":"Dier Mardi","owner_url":"/insider/0001574591","role":"Officer (Executive VP and CFO)","role_mark":"O","role_mark_label":"Officer (Executive VP and CFO)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Executive VP and CFO","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":93392.0,"shares_display":"93,392","price_per_share":55.46326462652047,"price_display":"55.46","price_state":"stated","total_value":5179825.21,"total_display":"5,179,825.21","total_whole":"5,179,825","shares_owned_after":4493.0,"shares_owned_after_display":"4,493","ownership_form":"D","is_10b5_1":null,"transaction_date":"2017-06-27","filed_date":"2017-06-28","scope":"insider","n_lines":3},{"id":5201499,"accession":"0001209191-17-021197","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001209191-17-021197","line_url":"/filing/0001209191-17-021197#line-3","is_derivative":false,"issuer_cik":"0001269021","issuer_name":"PORTOLA PHARMACEUTICALS INC","issuer_ticker":"PTLA","issuer_name_source":null,"issuer_url":"/issuer/0001269021","owner_cik":"0001574591","owner_name":"Dier Mardi","owner_display_name":"Dier Mardi","owner_url":"/insider/0001574591","role":"Officer (Executive VP and CFO)","role_mark":"O","role_mark_label":"Officer (Executive VP and CFO)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Executive VP and CFO","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":10235.0,"shares_display":"10,235","price_per_share":40.02,"price_display":"40.02","price_state":"stated","total_value":409604.7,"total_display":"409,604.70","total_whole":"409,605","shares_owned_after":0.0,"shares_owned_after_display":"0","ownership_form":"D","is_10b5_1":null,"transaction_date":"2017-03-15","filed_date":"2017-03-16","scope":"insider"},{"id":8345966,"accession":"0001209191-15-071559","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001209191-15-071559","line_url":"/filing/0001209191-15-071559#line-4","is_derivative":false,"issuer_cik":"0001269021","issuer_name":"PORTOLA PHARMACEUTICALS INC","issuer_ticker":"PTLA","issuer_name_source":null,"issuer_url":"/issuer/0001269021","owner_cik":"0001574591","owner_name":"Dier Mardi","owner_display_name":"Dier Mardi","owner_url":"/insider/0001574591","role":"Officer (Executive VP and CFO)","role_mark":"O","role_mark_label":"Officer (Executive VP and CFO)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Executive VP and CFO","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":8912.0,"shares_display":"8,912","price_per_share":55.0,"price_display":"55.00","price_state":"stated","total_value":490160.0,"total_display":"490,160.00","total_whole":"490,160","shares_owned_after":0.0,"shares_owned_after_display":"0","ownership_form":"D","is_10b5_1":null,"transaction_date":"2015-09-18","filed_date":"2015-09-21","scope":"insider"},{"id":8847971,"accession":"0001209191-15-051541","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001209191-15-051541","line_url":"/filing/0001209191-15-051541#line-3","is_derivative":false,"issuer_cik":"0001269021","issuer_name":"PORTOLA PHARMACEUTICALS INC","issuer_ticker":"PTLA","issuer_name_source":null,"issuer_url":"/issuer/0001269021","owner_cik":"0001574591","owner_name":"Dier Mardi","owner_display_name":"Dier Mardi","owner_url":"/insider/0001574591","role":"Officer (Executive VP and CFO)","role_mark":"O","role_mark_label":"Officer (Executive VP and CFO)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Executive VP and CFO","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":16119.0,"shares_display":"16,119","price_per_share":43.0,"price_display":"43.00","price_state":"stated","total_value":693117.0,"total_display":"693,117.00","total_whole":"693,117","shares_owned_after":0.0,"shares_owned_after_display":"0","ownership_form":"D","is_10b5_1":null,"transaction_date":"2015-06-08","filed_date":"2015-06-09","scope":"insider"},{"id":8750200,"accession":"0001209191-15-047249","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-15-047249","line_url":"/filing/0001209191-15-047249#line-2","is_derivative":false,"issuer_cik":"0001269021","issuer_name":"PORTOLA PHARMACEUTICALS INC","issuer_ticker":"PTLA","issuer_name_source":null,"issuer_url":"/issuer/0001269021","owner_cik":"0001574591","owner_name":"Dier Mardi","owner_display_name":"Dier Mardi","owner_url":"/insider/0001574591","role":"Officer (Executive VP and CFO)","role_mark":"O","role_mark_label":"Officer (Executive VP and CFO)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Executive VP and CFO","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":6076.0,"shares_display":"6,076","price_per_share":41.0,"price_display":"41.00","price_state":"stated","total_value":249116.0,"total_display":"249,116.00","total_whole":"249,116","shares_owned_after":0.0,"shares_owned_after_display":"0","ownership_form":"D","is_10b5_1":null,"transaction_date":"2015-05-27","filed_date":"2015-05-27","scope":"insider"}],"collapsed":true,"next_cursor":"2015-05-27|8750200","ledger_fault":false,"count":{"value":63,"kind":"exact"},"open_market_only":false,"composition":{"kind":"exact","rows":[{"code":"P","label":"Open-market purchase","n":4,"open_market":true},{"code":"S","label":"Open-market sale","n":59,"open_market":true},{"code":"M","label":"Option exercise","n":0,"open_market":false},{"code":"A","label":"Grant or award","n":0,"open_market":false},{"code":"F","label":"Tax withholding","n":0,"open_market":false},{"code":"D","label":"Disposition to the issuer","n":0,"open_market":false},{"code":"X","label":"In-the-money option exercise","n":0,"open_market":false}],"total":63},"affiliations":[{"type":"issuer","type_label":"ISSUER","cik":"0001157601","name":"MADRIGAL PHARMACEUTICALS, INC.","url":"/issuer/0001157601","role":"Officer (EVP and CFO)","n_filings":5,"first_seen":"2025-03-05","last_seen":"2026-03-06"},{"type":"issuer","type_label":"ISSUER","cik":"0001962918","name":"ACELYRIN, Inc.","url":"/issuer/0001962918","role":"Officer (CFO and CBO)","n_filings":1,"first_seen":"2023-05-11","last_seen":"2023-05-11"},{"type":"issuer","type_label":"ISSUER","cik":"0001515673","name":"Ultragenyx Pharmaceutical Inc.","url":"/issuer/0001515673","role":"Officer (CFO & Executive Vice President)","n_filings":4,"first_seen":"2021-10-14","last_seen":"2022-10-17"},{"type":"issuer","type_label":"ISSUER","cik":"0001678660","name":"Prelude Therapeutics Inc","url":"/issuer/0001678660","role":"Director","n_filings":1,"first_seen":"2020-09-29","last_seen":"2020-09-29"},{"type":"issuer","type_label":"ISSUER","cik":"0001269021","name":"PORTOLA PHARMACEUTICALS INC","url":"/issuer/0001269021","role":"Officer (EVP, CFO & CBO)","n_filings":18,"first_seen":"2014-03-27","last_seen":"2019-04-08"}],"order_statement":"Newest transaction date first, id breaking the tie.","canonical_url":"https://ebomi.com/insider/0001574591","retrieved_at":"2026-08-25T16:27:34+00:00","coverage":{"filings":1506293,"transactions":4290787,"issuers":28597,"insiders":152303,"first_filed_date":"2003-06-30","last_filed_date":"2026-08-24","last_ingest":"2026-08-25T05:24:19.374141+00:00","counts_are":{"filings":"estimate","transactions":"estimate","issuers":"estimate","insiders":"estimate"},"source":"SEC EDGAR Form 4 filings, parsed by ebomi","fault":false},"license":{"underlying_records":"US SEC filings are public records of the United States government and are not subject to copyright. The transactional facts in them are not ours to license.","this_presentation":"The parsing, normalisation, curation, and presentation are ebomi's own work.","grant":"undecided","grant_note":"The open licence for ebomi's own layer is an open owner decision (SPEC-20260731T1159Z open question 3: CC BY 4.0 or CC0 with a citation request). Until it is taken, no grant is asserted here.","citation_request":"Balogh, A. Insider trading. Scientific Data 10, 237 (2023)","url":"https://ebomi.com/license"},"fair_use":{"policy":"These JSON endpoints are open and unauthenticated. Please read them at a human pace, identify your client in the User-Agent header, and use the published dataset for bulk work rather than crawling page by page.","bulk_alternative":"doi:10.1038/s41597-023-02147-6"}}